ISPC Stock Forecast 2022, 2023, 2024, 2025, 2030

iSpecimen Inc Stock, an online platform for human biospecimens, rose 93% to $9.49 after the business explored arrangements with various “government and commercial researchers” for Covid-19-related study.

“In the previous 10 months, iSpecimen Inc has collaborated with several study and health care institutions on a number of projects needing a variety of COVID-19 data, such as nasal swabs, saliva, and blood products,” the company stated.

According to iSpecimen Inc, it recently delivered hundreds of biospecimens for continuing Covid-19 study by the United States military. As per iSpecimen Inc, the specimens, which include positive SARS-CoV-2 tests and negative controls, help experts calibrate testing equipment, analyze changes in antibody levels, and track transmission among close contacts.

EF Hutton boosted its iSpecimen Stock price objective to $12 from $10.

What Does iSpecimen Inc Do?

iSpecimen Inc develops a system that links life science researchers in need of human biofluids, tissues, and live cells with biospecimens accessible in medical provider organizations around the world. Researchers may use its cloud-based technology to explore for specimens and patients throughout a network of hospitals, labs, biobanks, blood centers, and some other healthcare institutions. The firm creates and runs iSpecimen Marketplace, a unique online marketplace system that links medical experts in need of people, materials, and statistics with hospitals, laboratories, as well as other institutions who have those. It offers biopharmaceutical firms, in vitro diagnostic firms, and government/academic organizations. iSpecimen Inc was founded in 2009 and is based in Lexington, Massachusetts.

What Is ISPC Stock Today?

Currently, the ISPC Stock Price is 11.620 USD today.

Below, you can check the ISPC Stock Forecast for the next days.

Date	ISPC Stock Price	Min ISPC Stock Price	Max ISPC Stock Price
2021-11-24	Price: 8.640	Min: 7.369	Max: 9.930
2021-11-25	Price: 8.409	Min: 7.085	Max: 9.565
2021-11-26	Price: 8.401	Min: 7.124	Max: 9.694
2021-11-29	Price: 9.201	Min: 7.894	Max: 10.458
2021-11-30	Price: 8.324	Min: 7.128	Max: 9.612
2021-12-01	Price: 8.231	Min: 7.083	Max: 9.450
2021-12-02	Price: 8.001	Min: 6.681	Max: 9.209
2021-12-03	Price: 7.992	Min: 6.778	Max: 9.281
2021-12-06	Price: 8.793	Min: 7.661	Max: 10.030

Is iSpecimen Inc Stock a Good Buy?

Is iSpecimen Inc Stock a Good Buy

ISPC Stock and perhaps its market situation have been in a negative term during the previous 12 months, as per current price data of iSpecimen Inc Stock. There appears to be a pattern in which stocks in the Professional, Scientific, and Technical Services industries are not particularly popular at the moment. A significant ISPC Stock Forecast expert predicts a downward trend in the future and that ISPC Stock is not a smart investment for making income. Because ISPC Stock Forecast has a bad outlook, we recommend exploring alternative companies to construct a portfolio instead.

Historical ISPC Stock Price Data:

Previous Market Cap: 81.3 M
ISPC Stock Price in USD (Previous Close): 8.880
iSpecimen IncStock Volume (Previous Close): 25.31 M
ISPC Stock Price in USD (Last): 11.620
90-Day Moving Average of iSpecimen IncStock: 6.383
52 Week High ISPC Stock Price: 10
52 Week Low ISPC Stock Price: 4.75
ISPC Stock Price’s 50 Day Moving Average: 6.22
200 Day Moving Average of ISPC Stock Price: 6.22

14 Days Historical Data

Date	Opening ISPC Stock Price	Closing ISPC Stock Price	Minimum ISPC Stock Price	Maximum ISPC Stock Price
2021-11-22	Open: 10.37	Close: 8.88	Low: 8.37	High: 11.31
2021-11-19	Open: 4.98	Close: 4.92	Low: 4.92	High: 4.98
2021-11-18	Open: 4.995	Close: 4.82	Low: 4.81	High: 5.04
2021-11-17	Open: 5.16	Close: 4.8	Low: 4.8	High: 5.18
2021-11-16	Open: 5.26	Close: 5.12	Low: 5.12	High: 5.28
2021-11-15	Open: 5.59	Close: 5.235	Low: 5.21	High: 5.59
2021-11-12	Open: 5.9	Close: 5.905	Low: 5.9	High: 5.905
2021-11-11	Open: 5.94	Close: 5.7	Low: 5.7	High: 5.94
2021-11-10	Open: 5.705	Close: 5.92	Low: 5.705	High: 5.92
2021-11-09	Open: 6.02	Close: 5.76	Low: 5.71	High: 6.02
2021-11-08	Open: 5.63	Close: 5.77	Low: 5.63	High: 5.77
2021-11-05	Open: 6.105	Close: 5.95	Low: 5.88	High: 6.105
2021-11-04	Open: 6.61	Close: 6.32	Low: 6.26	High: 6.61
2021-11-03	Open: 7.74	Close: 7.4	Low: 7.4	High: 7.83

Top Institutional Holders of ISPC Stock

Holder	Shares	Date Reported	% Out	Value
Bleichroeder LP	618,180	Sep 29, 2021	8.84%	3,607,080
Kepos Capital Lp	225,000	Sep 29, 2021	3.22%	1,312,875
Millennium Management LLC	27,677	Sep 29, 2021	0.40%	161,495
Telemus Capital, LLC	24,400	Sep 29, 2021	0.35%	142,374
Citadel Advisors LLC	12,755	Sep 29, 2021	0.18%	74,425
Blackrock Inc.	6,007	Sep 29, 2021	0.09%	35,050
Tower Research Capital LLC (TRC)	1,365	Sep 29, 2021	0.02%	7,964
Total Clarity Wealth Management, Inc.	942	Sep 29, 2021	0.01%	5,496

Top Mutual Fund Holders of ISPC Stock

Holder	Shares	Date Reported	% Out	Value
iShares Micro Cap ETF	5,424	Sep 29, 2021	0.08%	31,649
Fidelity NASDAQ Composite Index Fund	2,160	Sep 29, 2021	0.03%	12,603

ISPC Stock Price News

iSpecimen Inc Stock Price (NASDAQ: ISPC) rose by more than 135 percent today. This is why it occurred.

iSpecimen Inc Stock Price (NASDAQ: ISPC), an online platform for human biospecimens, rose by more than 135 percent pre-market this trading day. Traders are responding favorably to iSpecimen’s announcement that it has been contracted to fund more important study on COVID-19, seeking information on its transmissibility, variations, consequences, and testing validity across numerous population segments. In the previous ten months, iSpecimen Inc has collaborated with a number of scientific and health care institutions on a lot of projects needing a variety of COVID-19 materials, notably nose swabs, saliva, and lab tests.

iSpecimen Inc’s work on COVID-19 started shortly after the epidemic last year, whenever it began submitting serum samples to the Centers for Disease Control and Prevention in order to assist scientists in analyzing antibody production for possible advice on protection. Furthermore, iSpecimen Inc supplied the Centers for Disease Control and Prevention (CDC) with 600 SARS-CoV-2-positive serum tests and 100 neg serum tests, the majority of which were lab test residues.

iSpecimen Inc has also been hired by other government agencies and commercial organizations for bespoke COVID-19 collections, which are frequently complicated and supplement the more rapid accessibility of residual or banked materials.

In addition to its cooperation with the CDC, iSpecimen Inc has recently contributed hundreds of humans biospecimens to the US military’s continuing COVID-19 study. Furthermore, the materials, which include positive SARS-CoV-2 tests as well as negative controls, aid scientists in validating COVID-19 testing systems, understanding changes in patients’ antibody levels, controlling transmission among direct ties, and other tasks.

Another research established by iSpecimen Inc involves COVID-19 study participants – together with their relatives, households, or other individuals with whom they communicate. If any further subjects have COVID-like signs in the two weeks following the first subject’s testing, the second subject can require a follow-up blood sample for an analysis.

In some other investigation, blood tests are being obtained from symptomatic patients who already have tested positive for COVID-19, and most of those same patients will reappear two months later as part of a longitudinal assessment of how their biology, such as antibody levels, has altered. The tests are frequently obtained from a number of regions and represent a wide range of ages, races, and ethnicities. In certain circumstances, tests are also genetically scanned in order to discover variations.

In support of data analysis tasks that require a continuous stream of various types of samples from each subject of study – as many as 21 samples, such as nasal swabs, oral swabs, saliva, and blood products in different forms and amounts, have been collected and supplied from people in recruited cohorts.

iSpecimen Inc has also just added a new partnership to give scientists with genetically analyzed and classified SARS-CoV-2 variant swabs and biofluid data.